Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>uniQure is a pioneering gene therapy company with one approved product, HEMGENIX®, for Hemophilia B, which is the first and only gene therapy for this indication, commercialized by its partner CSL Behring.</li>
  <li>The company's lead pipeline candidate, AMT-130 for Huntington's disease, has shown statistically significant slowing of disease progression in a pivotal Phase I/II study and has received multiple expedited regulatory designations from the FDA, including Breakthrough Therapy and RMAT.</li>
  <li>While possessing a promising pipeline and validated technology, uniQure is currently unprofitable, with significant cash burn from R&amp;D activities, making future value creation highly dependent on the clinical success and commercial uptake of its key assets, particularly AMT-130.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  uniQure is a pioneering gene therapy company with one approved product, HEMGENIX®, for Hemophilia B, which is the first and only gene therapy for this indication, commercialized by its partner CSL Behring.
  The company's lead pipeline candidate, AMT-130 for Huntington's disease, has shown statistically significant slowing of disease progression in a pivotal Phase I/II study and has received multiple expedited regulatory designations from the FDA, including Breakthrough Therapy and RMAT.
  While possessing a promising pipeline and validated technology, uniQure is currently unprofitable, with significant cash burn from R&amp;D activities, making future value creation highly dependent on the clinical success and commercial uptake of its key assets, particularly AMT-130.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Netherlands

uniQure N.V. delivers gene therapy with single treatments for curative results. The Company develops a modular platform to bring new disease modifying therapies to patients with severe genetic diseases, as well as offers ongoing clinical programs in hemophilia B and pre-clinical proof-of-concept in Huntington's disease.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

uniQure NV (QURE US)

Primer: uniQure NV (QURE US) - Sep 2025

uniQure is a pioneering gene therapy company with one approved product, HEMGENIX®, for Hemophilia B, which is the first and only gene therapy...

αSK

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)